Gilead Sciences (GILD) Net Cash Flow Growth (1y) (2010 - 2026)
Gilead Sciences (GILD) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 195.58% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -0.70% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 349.49% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -55.11% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -517.34% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 78.10% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -99.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.11% |
| Mar 31, 2026 | 103.60% |
| Dec 31, 2025 | -95.43% |
| Sep 30, 2025 | -1.26% |
| Jun 30, 2025 | -47.60% |
| Mar 31, 2025 | -54.48% |
| Dec 31, 2024 | 1,360.64% |
| Sep 30, 2024 | 31,614.29% |
| Jun 30, 2024 | -356.63% |
| Mar 31, 2024 | -176.43% |
| Dec 31, 2023 | -46.24% |
| Sep 30, 2023 | -78.13% |
| Jun 30, 2023 | 53.56% |
| Mar 31, 2023 | 52.34% |
| Dec 31, 2022 | -35.23% |
| Sep 30, 2022 | 106.30% |
| Jun 30, 2022 | -39.23% |
| Mar 31, 2022 | 46.36% |
| Dec 31, 2021 | 114.21% |
| Sep 30, 2021 | -108.32% |